•
China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its branch in Boston, USA, marking a significant step in the company’s global expansion strategy. Enhancing International Collaboration NetworksThe establishment of the Boston branch is expected to significantly enhance VIVA Bio’s international collaboration networks. This move…
•
Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced Accelerator Applications (AAA) Molecular Imaging from Novartis (NYSE: NVS). This strategic move is anticipated to significantly enhance Siemens’ PETNET Solutions sector, strengthening its position in the field of positron emission tomography (PET) and radiopharmaceuticals. Enhancing…
•
Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and California, the US, has announced the successful closing of a USD 120 million Series C financing round. The funding was led by Bain Capital Life Sciences and included contributions from Janus Henderson and existing investors…
•
China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds of millions of renminbi in a Series C++ financing round, led by FUN WAY AMC. The proceeds from this funding will be directed towards the development and operation of the company’s consumer healthcare and life…
•
Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech Co., Ltd., and AccurEdit Therapeutics will be housed at its Bayer Co.Lab Shanghai. This move aims to leverage Bayer’s global innovation and cooperation network, connecting global pharmaceutical industry resources to boost cell and gene therapy…
•
UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA study for its PARP inhibitor Lynparza (olaparib) at the San Antonio Breast Cancer Symposium 2024 (SABCS). The study provides significant insights into the efficacy and safety of Lynparza in patients with germline BRCA-mutated (gBRCAm) HER2-negative…
•
Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food and Drug Administration (FDA) for its combination vaccine candidates aimed at preventing influenza and COVID-19 infections in individuals aged 50 and older. Details of the Combination Vaccine CandidatesOne of the combination vaccine candidates (NCT06695117) pairs…
•
China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm Livzon Pharmaceutical Group Inc. (HKG: 1513), marking a significant step in the global development of a novel small interfering RNA (siRNA) product for the treatment of metabolic diseases. Terms of the Licensing AgreementUnder the agreement,…
•
Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the first quarter of 2025, marking a significant step in the company’s expansion into digital health solutions. Alongside this acquisition, Bayer is initiating the commercialization of its digital health application, Cara Care, which is designed to…
•
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase III EMBER-3 study for its drug imlunestrant in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). The study focused on patients whose disease progressed on…
•
Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech Ltd, a London-headquartered cell and gene therapy (CGT) manufacturing technology leader. The partnership aims to integrate the IRO platform with Fresenius Kabi’s Cue and Lovo Cell Processing Systems, marking a significant step in the advancement…
•
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data from the ongoing Phase Ib portion of the TACTIVE-U sub-study at the 2024 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The study assesses vepdegestrant in combination with Verzenios (abemaciclib) in patients with…
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has formed two multi-program strategic partnerships with compatriot firm Relation Therapeutics. These deals are focused on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis, with GSK obtaining global development and commercialization rights to any resultant targets. Financial Terms…
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE study for its Kisqali (ribociclib) at the 2024 San Antonio Breast Cancer Symposium (SABCS). The study provides significant insights into the efficacy of Kisqali in combination with endocrine therapy (ET) for patients with receptor-positive/human epidermal…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD) negativity rates from the Phase III CARTITUDE-4 trial at the 66th Annual American Society of Hematology (ASH) Annual Meeting. The trial compared Carvykti (ciltacabtagene autoleucel; cilta-cel) with the standard of care (SoC) in treating multiple…
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its Arcalyst (rilonacept), a treatment for recurrent pericarditis (RP). This marks an expansion of the drug’s application in addressing autoimmune diseases. Rilonacept’s Mechanism and Global ApprovalsRilonacept is a recombinant…
•
China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its recombinant human hyaluronidase for injection. The study aims to explore the use of the drug to promote the diffusion of subcutaneous infusion as an…
•
Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has received approval from China’s National Medical Products Administration (NMPA) to initiate a clinical study for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cells), LYB005. LYB005’s U-VLP Technology and Clinical ProgressLYB005 is an RSV vaccine…
•
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its SRD4610, an in-house developed compound Chinese medicine, for the treatment of amyotrophic lateral sclerosis (ALS). This designation highlights the potential impact of SRD4610 in…
•
China-based rare disease specialist Sperogenix Therapeutics Limited has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its drug Agamree (vamorolone), which is used to treat patients with Duchenne muscular dystrophy (DMD). This marks a significant milestone as Agamree becomes the first DMD drug approved in China,…